コンテンツへスキップ
Merck
  • The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns.

The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns.

Surgical endoscopy (2014-10-09)
Hendrik Manner, Oliver Pech, Yvonne Heldmann, Andrea May, Michael Pauthner, Dietmar Lorenz, Annette Fisseler-Eckhoff, Manfred Stolte, Michael Vieth, Christian Ell
要旨

A prerequisite for endoscopic treatment (ET) of not only mucosal, but also submucosal early adenocarcinoma of the esophagus (EAC) would be a rate of lymph node (LN) metastasis below the mortality rate of esophagectomy (2-5%). The aim of the present study was to evaluate the rate of LN metastasis in patients with pT1b sm1 EAC. 1996-2010, 1,718 patients with suspicion of EAC were referred to the Department of Internal Medicine II at HSK Wiesbaden. In 123/1718 patients, the suspicion (endoscopic ultrasound, EUS) or definitive diagnosis of sm1 EAC (ER/surgery) was made. Rate of LN metastasis was analyzed separately for low-risk (LR; G1-2, L0, V0) and high-risk lesions (HR; G3, L1, V1; ≥ 1 risk factor). LN metastasis was only evaluated in patients who had a proven maximum invasion depth of sm1 (ER and/or surgery), and who in case of ET had a follow-up (FU) by EUS of at least 24 months. Of the 72/123 patients included into the study, 49 patients had LR (68%) and 23 HR lesions (32%). In endoscopically treated LR patients (37/49), mean EUS-FU was 60 ± 30 mo (range 25-146); in HR patients undergoing ET (6/23), it was 63 ± 17 mo (46-86; p = 0.4). Mean number of resected LN was 27 ± 16 (12-62) in operated LR patients and 27 ± 10 (12-47) in HR-patients. The rate of LN metastasis was 2% in the LR (1 patient) and 9% in the HR group (2 patients; p = 0.24). Mortality of esophagectomy was 3%. The rate of LN metastasis in pT1b sm1 early adenocarcinoma with histological LR pattern was lower than the mortality rate of esophagectomy. ER may therefore be used alternatively to surgery in this group of patients.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
メチレンブルー, certified by the BSC
Sigma-Aldrich
メチレンブルー 溶液, concentrate according to Ehrlich, concentrated, aqueous solution
Sigma-Aldrich
酢酸, suitable for luminescence, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
5α-アンドロスタン-17β-オール-3-オン, ≥97.5%
Sigma-Aldrich
酢酸, ≥99.7%
Sigma-Aldrich
酢酸, ≥99.5%, FCC, FG
Sigma-Aldrich
酢酸, natural, ≥99.5%, FG
Sigma-Aldrich
酢酸, JIS special grade, ≥99.7%
Sigma-Aldrich
メチレンブルー 溶液, 0.05 wt. % in H2O
Sigma-Aldrich
酢酸 溶液, 1 N, 1 M
Sigma-Aldrich
酢酸, SAJ first grade, ≥99.0%
Sigma-Aldrich
メチレンブルー 溶液
Sigma-Aldrich
5α-アンドロスタン-17β-オール-3-オン, purum, ≥99.0% (TLC)
Sigma-Aldrich
メチレンブルー 溶液, 1.4 % (w/v) in 95% ethanol
Sigma-Aldrich
N-アセチル-D-ラクトサミン, ≥98% (TLC)
Sigma-Aldrich
酢酸, ≥99.7%, SAJ super special grade
Sigma-Aldrich
酢酸, ≥99.7%, for titration in non-aqueous medium
Sigma-Aldrich
Acetic acid-12C2, 99.9 atom % 12C
Sigma-Aldrich
酢酸, 99.5-100.0%
Sigma-Aldrich
酢酸 溶液, SAJ first grade, 27.0-33.0%